Smith & Nephew plc: Q1 2026 Trading Update Summary
Business Context and Reporting Period
This Form 6-K filing reports the First Quarter 2026 trading update for Smith & Nephew plc, a global medical technology company focused on Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The reporting period covers the quarter ended March 28, 2026. The company operates in approximately 100 countries and is a constituent of the FTSE100 and NYSE.
Key Financial Metrics
- Revenue: Q1 2026 reported revenue was $1,501 million, compared to $1,407 million in Q1 2025. This represents reported growth of 6.6% and underlying growth of 3.1%.
- Adjusted Daily Sales (ADS): Underlying revenue growth on an ADS basis was 4.7%, accounting for one fewer trading day in Q1 2026 versus the prior year.
- Currency Impact: A 350 basis point tailwind from foreign exchange (primarily Euro strengthening against USD) contributed to reported growth.
- Profitability & Cash Flow: Full-year 2026 trading profit is expected to be around $1.3 billion (post-acquisition of Integrity Orthopaedics). Full-year free cash flow guidance is approximately $800 million.
- Capital Allocation: A new $500 million share buyback was announced, to be completed within 12 months, financed by free cash flow and existing balances.
Material Changes vs. Prior Period
- Sports Medicine & ENT: Reported revenue grew 10.4% to $491 million. Sports Medicine Joint Repair grew 13.8% (reported), driven by shoulder repair portfolios (REGENETEN, Q-FIX) and cartilage repair (CARTIHEAL). ENT declined 7.2% due to channel inventory reduction in China ahead of Volume-Based Procurement (VBP).
- Advanced Wound Management: Reported revenue grew 6.6% to $411 million. Advanced Wound Care grew 11.7%, while Advanced Wound Bioactives declined 1.1% due to a reimbursement reset for skin substitutes in the US.
- Orthopaedics: Reported revenue grew 3.7% to $599 million. Hip Implants grew 7.3% (reported), outperforming the market. US Knee Implants declined 10.3% (underlying) due to deliberate trade-offs ahead of the new LANDMARK system launch, while non-US Knee Implants grew 6.0% (underlying).
- Geography: Emerging Markets grew 16.0% (reported), led by China. Other Established Markets grew 9.8% (reported), driven by currency tailwinds. The US grew 2.1% (reported).
Guidance, Outlook, and Management Commentary
Management reaffirmed full-year 2026 guidance, expecting underlying revenue growth of around 6% and trading profit growth of around 8%. The company anticipates a stronger second half of the year driven by product launches, stabilization in the skin substitutes market, and an improving trajectory in US Knee Implants.
- Strategy: The "RISE" strategy is on track, focusing on reaching more patients, innovating (e.g., REGENETEN clinical data), scaling via acquisitions (Integrity Orthopaedics), and executing efficiently via AI and supply chain optimization.
- Risks & Contingencies: Key headwinds include a $60 million tariff impact and a $20-$40 million impact from the skin substitute reimbursement reset. The acquisition of Integrity Orthopaedics is expected to be marginally dilutive to trading profit in 2026.
- Leadership Change: Nathan Folkert has been appointed President of Orthopaedics, replacing Craig Gaffin.
Investor Verification Checklist
- Verify the timeline and market impact of the US skin substitute reimbursement reset on Advanced Wound Bioactives volumes and pricing.
- Monitor the launch and adoption rates of the new LANDMARK Knee System (Q3 2026) to confirm the anticipated recovery in US Knee Implants.
- Assess the integration progress and financial contribution of the Integrity Orthopaedics acquisition.
- Track the implementation of Volume-Based Procurement (VBP) in China for both Sports Medicine and ENT segments in H2 2026.
- Confirm the execution of the $500 million share buyback and its impact on share count and earnings per share.